Bristol-Myers Squibb Company announced a global collaboration with Nissan Chemical Industries, Ltd and Teijin Pharma Limited for the development and commercialization of NTC-801, a selective inhibitor of the acetylcholine-activated potassium ion channel (IKACh), currently in phase-I development in Japan, for the maintenance of normal sinus rhythm in patients with atrial fibrillation.
The details can be read here.
No comments:
Post a Comment